Results 221 to 230 of about 117,595 (294)

Characterisation of Antisense Oligonucleotides by Ion-Pair Reversed-Phase UHPLC-HRMS: Method development using Design of Experiments. [PDF]

J Mass Spectrom
Triolo A, Tavani F, Barnini P, Furlanetto S, Orlandini S.   +4 more
europepmc   +1 more source

Viral and non-viral cellular therapies for neurodegeneration. [PDF]

Front Med (Lausanne)
Srivastav J, Sharma S.
europepmc   +1 more source

Discovery of long-acting APOC3 siRNA for treating patients with hypertriglyceridemia. [PDF]

Nucleic Acids Res
Prakash TP, Mullick AE, Riney S, Yu J, Nikan M, Quirk C, Crutchfield A, Damle SS, Klein S, Swayze EE.   +9 more
europepmc   +1 more source

Angiopoietin-like Protein 3 (ANGPTL3) Targeting in the Management of Dyslipidemias. [PDF]

Int J Mol Sci
Kosmas CE, Rallidis LS, Hoursalas I, Papakonstantinou EJ, Kostara CE.   +4 more
europepmc   +1 more source

Gene expression silencing therapy in tumors, focus on gastrointestinal and genitourinary tumors. [PDF]

Front Immunol
El-Ghazzi N, Italiano A, Angeli E.
europepmc   +1 more source

Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions. [PDF]

Front Pharmacol
Cronin JM, Yu AM.
europepmc   +1 more source

Targeting Non-Coding RNAs as a Potential Therapeutic and Delivery Strategy Against Neurodegenerative Diseases. [PDF]

Int J Mol Sci
Bougea A.
europepmc   +1 more source

Bioconjugates for improved delivery of oligonucleotide therapeutics to the central nervous system. [PDF]

Adv Drug Deliv Rev
Lee HJ, Xie Y, Greineder CF, Tessier PM.
europepmc   +1 more source

Broad-spectrum antiviral activity of antisense oligonucleotides targeting GBF1 against SARS-CoV-2 and influenza viruses. [PDF]

iScience
Simanihuruk V, Kida Y, Takada K, Yamaguma H, Kameoka N, Anzai I, Shichinohe S, Obika S, Kasahara Y, Watanabe T.   +9 more
europepmc   +1 more source